Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
A new Pharmakon credit facility extends PGEN's cash runway into at least 2027, with management targeting cash-flow breakeven by the end of 2026. PAPZIMEOS' net price is ~$400,000 per patient annually, and redosing/early-line adoption could drive long-term revenue growth beyond severe RRP cases. Risks include single asset dependency, payer pushback, competition from INO-3107, and execution on breakeven, but the opportunity remains compelling at current valuation. German Adrasti/E+ via Getty Images Introduction There have been some notable developments at Precigen, Inc. ( PGEN ) since my last look in mid-August. My Buy rating followed the FDA approval of PAPZIMEOS for adults with recurrent respiratory papillomatosis, or RRP, a This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]Seeking Alpha
- Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]Yahoo! Finance
- Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 [Yahoo! Finance]Yahoo! Finance
- Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13PR Newswire
PGEN
Earnings
- 11/13/25 - Miss
PGEN
Sec Filings
- 11/21/25 - Form SCHEDULE
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- PGEN's page on the SEC website